Publications by authors named "G Lichtenstein"
Article Synopsis
- Interleukin-23 inhibition is a promising treatment for ulcerative colitis, and guselkumab serves as a potent inhibitor targeting this pathway, aiming to assess its safety and effectiveness for patients who have not responded to traditional therapies.
- The study included two phase 3 trials where adults with moderate to severe active ulcerative colitis were randomly assigned to receive guselkumab or a placebo, with a focus on clinical remission as the main outcome at specific time points.
- Results showed that a significantly higher number of patients receiving guselkumab achieved clinical remission compared to those on placebo, highlighting its potential as an effective therapy for managing ulcerative colitis.
Endoscopy plays a key role in diagnosis, monitoring of disease activity, assessment of treatment response, dysplasia surveillance, postoperative evaluation, and interventional therapy for patients with inflammatory bowel disease (IBD). Clinical practice patterns in the endoscopic management of IBD vary. A panel of experts consisting of IBD specialists, endoscopists, and GI pathologists participated in virtual conferences and developed this modified Delphi-based consensus document to address endoscopic aspects of IBD management.
View Article and Find Full Text PDFExploring the Use of Biosimilars to Treat Patients With Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
July 2024
Examining Pharmacoequity in Older Inflammatory Bowel Disease Patients.
Gastroenterol Hepatol (N Y)
August 2024